Mass spectrometry MALDI imaging of colon cancer biomarkers: A new diagnostic paradigm

Paul H. Pevsner; Jonathan Melamed; Tiffany Remsen; Alexander Kogos; Fritz Francois; Paul Kessler; Arnold Stern; Sury Anand

doi:10.2217/17520363.3.1.55

Mass spectrometry MALDI imaging of colon cancer biomarkers: A new diagnostic paradigm

Paul H. Pevsner, Jonathan Melamed, Tiffany Remsen, Alexander Kogos, Fritz Francois, Paul Kessler, Arnold Stern, Sury Anand

Research output: Contribution to journal › Review article › peer-review

23 Scopus citations

Abstract

Colorectal cancer (CRC), is the second-leading cause of cancer-related deaths in the USA, affecting both men and women. Current projections show little or no change since the publication of a morbidity and mortality study in 2005. The projected number of new cases for 2008 is 154,000, and the projected number of CRC cancer deaths for 2008 is 53,000. The standard diagnostic paradigm is based on histopathology of either biopsy or surgical specimens. This article suggests a new paradigm for colon cancer diagnosis and staging using matrix-assisted laser desorption/ionization imaging mass spectrometry (MALDI IMS or IMS). IMS may identify potential tumors in normal tissue of cancer patients and predict those cancer patients who are at risk for recurrent cancer.

Original language	English
Pages (from-to)	55-69
Number of pages	15
Journal	Biomarkers in Medicine
Volume	3
Issue number	1
DOIs	https://doi.org/10.2217/17520363.3.1.55
State	Published - 2009
Externally published	Yes

Keywords

Biomarker
Colorectal cancer
Imaging
LCMS
Liquid chromatography mass spectrometry
MALDI IMS
Mass spectrometry
Matrix-assisted laser desorption/ionization imaging mass spectrometry

Access to Document

10.2217/17520363.3.1.55

Cite this

@article{aa61f137da3e489cab95e787810d97be,

title = "Mass spectrometry MALDI imaging of colon cancer biomarkers: A new diagnostic paradigm",

abstract = "Colorectal cancer (CRC), is the second-leading cause of cancer-related deaths in the USA, affecting both men and women. Current projections show little or no change since the publication of a morbidity and mortality study in 2005. The projected number of new cases for 2008 is 154,000, and the projected number of CRC cancer deaths for 2008 is 53,000. The standard diagnostic paradigm is based on histopathology of either biopsy or surgical specimens. This article suggests a new paradigm for colon cancer diagnosis and staging using matrix-assisted laser desorption/ionization imaging mass spectrometry (MALDI IMS or IMS). IMS may identify potential tumors in normal tissue of cancer patients and predict those cancer patients who are at risk for recurrent cancer.",

keywords = "Biomarker, Colorectal cancer, Imaging, LCMS, Liquid chromatography mass spectrometry, MALDI IMS, Mass spectrometry, Matrix-assisted laser desorption/ionization imaging mass spectrometry",

author = "Pevsner, \{Paul H.\} and Jonathan Melamed and Tiffany Remsen and Alexander Kogos and Fritz Francois and Paul Kessler and Arnold Stern and Sury Anand",

year = "2009",

doi = "10.2217/17520363.3.1.55",

language = "English",

volume = "3",

pages = "55--69",

journal = "Biomarkers in Medicine",

issn = "1752-0363",

publisher = "Taylor and Francis Ltd.",

number = "1",

}

TY - JOUR

T1 - Mass spectrometry MALDI imaging of colon cancer biomarkers

T2 - A new diagnostic paradigm

AU - Pevsner, Paul H.

AU - Melamed, Jonathan

AU - Remsen, Tiffany

AU - Kogos, Alexander

AU - Francois, Fritz

AU - Kessler, Paul

AU - Stern, Arnold

AU - Anand, Sury

PY - 2009

Y1 - 2009

N2 - Colorectal cancer (CRC), is the second-leading cause of cancer-related deaths in the USA, affecting both men and women. Current projections show little or no change since the publication of a morbidity and mortality study in 2005. The projected number of new cases for 2008 is 154,000, and the projected number of CRC cancer deaths for 2008 is 53,000. The standard diagnostic paradigm is based on histopathology of either biopsy or surgical specimens. This article suggests a new paradigm for colon cancer diagnosis and staging using matrix-assisted laser desorption/ionization imaging mass spectrometry (MALDI IMS or IMS). IMS may identify potential tumors in normal tissue of cancer patients and predict those cancer patients who are at risk for recurrent cancer.

AB - Colorectal cancer (CRC), is the second-leading cause of cancer-related deaths in the USA, affecting both men and women. Current projections show little or no change since the publication of a morbidity and mortality study in 2005. The projected number of new cases for 2008 is 154,000, and the projected number of CRC cancer deaths for 2008 is 53,000. The standard diagnostic paradigm is based on histopathology of either biopsy or surgical specimens. This article suggests a new paradigm for colon cancer diagnosis and staging using matrix-assisted laser desorption/ionization imaging mass spectrometry (MALDI IMS or IMS). IMS may identify potential tumors in normal tissue of cancer patients and predict those cancer patients who are at risk for recurrent cancer.

KW - Biomarker

KW - Colorectal cancer

KW - Imaging

KW - LCMS

KW - Liquid chromatography mass spectrometry

KW - MALDI IMS

KW - Mass spectrometry

KW - Matrix-assisted laser desorption/ionization imaging mass spectrometry

UR - https://www.scopus.com/pages/publications/68049083484

U2 - 10.2217/17520363.3.1.55

DO - 10.2217/17520363.3.1.55

M3 - Review article

AN - SCOPUS:68049083484

SN - 1752-0363

VL - 3

SP - 55

EP - 69

JO - Biomarkers in Medicine

JF - Biomarkers in Medicine

IS - 1

ER -

Mass spectrometry MALDI imaging of colon cancer biomarkers: A new diagnostic paradigm

Abstract

Keywords

Access to Document

Fingerprint

Cite this